Abstract
IntroductionGlomerulonephritis is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Deposition of autoantibodies in the glomeruli plays a key role in the development of lupus nephritis (LN). Different groups have proposed that either anti-nucleosome antibodies or antibodies that bind the intrinsic renal antigen, α-actinin, are central to the pathogenesis of LN. These theories have been based mainly on cross-sectional studies in patients and on experiments in animal models. No previous longitudinal studies have compared the relationships between levels of these antibodies and markers of renal function. We assessed how well anti-α-actinin, anti-nucleosome and anti-double-stranded DNA (anti-dsDNA) antibodies reflected renal outcome measures in patients with new-onset LN followed for up to 2 years.MethodsRenal disease activity was monitored by measuring urine protein/creatinine ratio (PCR), serum albumin and a composite outcome of renal remission. At each time point, anti-nucleosome and anti-α-actinin antibodies were measured by enzyme-linked immunosorbent assay. High-avidity anti-dsDNA antibodies were measured using the Farrzyme assay. We analysed relationships between levels of the three antibodies and between antibody levels and renal outcome measures over time.ResultsLevels of anti-nucleosome and anti-dsDNA were positively correlated with each other (r = 0.6, P = 0.0001) but neither correlated with anti-α-actinin level. At baseline, mean anti-nucleosome levels were higher in patients with LN than in healthy controls (0.32 versus 0.01, P < 0.001). The same was true for anti-dsDNA antibodies (0.50 versus 0.07, P < 0.001) but not for anti-α-actinin (0.33 versus 0.29). Over the follow-up period, anti-nucleosome and anti-dsDNA levels associated positively with urine PCR (P = 0.041 and 0.051, respectively) and negatively with serum albumin (P = 0.027 and 0.032, respectively). Both anti-nucleosome and anti-dsDNA levels were significantly lower during renal remission than when renal disease was active (P = 0.002 and 0.003, respectively). However, there was no relationship between anti-α-actinin levels and urine PCR, serum albumin or remission status.ConclusionsThis prospective longitudinal clinical study is the first to compare levels of anti-nucleosome, anti-dsDNA and anti-α-actinin antibodies in the same patients with SLE. Our results support the concept that, in the majority of patients, anti-nucleosome antibodies play a major role in pathogenesis of LN, in contrast to anti-α-actinin antibodies.
Highlights
Glomerulonephritis is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE)
This prospective longitudinal clinical study is the first to compare levels of anti-nucleosome, anti-dsDNA and antiα-actinin antibodies in the same patients with SLE
Our results support the concept that, in the majority of patients, antinucleosome antibodies play a major role in pathogenesis of lupus nephritis (LN), in contrast to anti-α-actinin antibodies
Summary
Glomerulonephritis is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Different groups have proposed that either anti-nucleosome antibodies or antibodies that bind the intrinsic renal antigen, α-actinin, are central to the pathogenesis of LN. These theories have been based mainly on cross-sectional studies in patients and on experiments in animal models. There are clearly some patients with persistently high anti-dsDNA levels who never develop LN [9] and there is no simple relationship between the ability of passively transferred monoclonal antibodies to bind dsDNA and the ability of the same antibodies to cause glomerulonephritis [5,6,7]. It has been argued that binding to nucleosomes is a major determinant of pathogenicity of autoantibodies in LN [13,14]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call